MedTrace Logo

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

NCT07446270 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-03-03

No results posted yet for this study

Summary

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

Conditions

  • Treatment for Advanced Colorectal Cancer
  • Treatment for Advanced Pancreatic Cancer

Interventions

DRUG

Colorectal cancer: Tunlametinib + cetuximab β

Colorectal cancer: Tunlametinib 6/9mg bid+ cetuximab β 500mg/m2

DRUG

Pancreatic cancer: Tunlametinib + cetuximab β

Pancreatic cancer: Tunlametinib 6/9mg+ cetuximab β 500mg/m2

DRUG

Pancreatic cancer: Tunlametinib +Nimotuzumab

Pancreatic cancer: Tunlametinib 6/9mg bid +Nimotuzumab 400mg

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-03
Primary Completion
2027-10-30
Completion
2028-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07446270 on ClinicalTrials.gov